BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor
Chong Li1,2, Ruping Yan3, Zhao Yang4
1Core Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Abstract:
Bladder cancer is one of the most common malignancies. However, there is no ideal therapy to cure bladder cancer so far, especially invasive carcinoma. Here, we developed a new antibody-based drug BCMab1-Ra, which was generated by conjugation of BCMab1 (a new monoclonal antibody that specifically recognized the aberrantly glycosylated Integrin a3b1 in bladder cancer) with the ricin A chain (Ra). A patient with multiple bladder cancer received intravescical administration of BCMab1-Ra treatment as a volunteer. After 30 weeks of treatment, no tumor was observed by cystoscope examination. We did not observe any local or systemic side effects. Human anti-mouse antibody (HAMA) was not detectable in the circulation. Results follow-up showed no tumor had been found in every half year review in 3 years.
Insights
A novel antibody-based drug, BCMab1-Ra, shows promise for treating invasive bladder cancer. A patient experienced no tumor recurrence or side effects after 30 weeks of intravesical treatment.
Area of Science:
- Oncology
- Immunotherapy
- Drug Development
Background:
- Bladder cancer, particularly invasive carcinoma, lacks ideal therapeutic options.
- Integrin α3β1, aberrantly glycosylated, is a potential target in bladder cancer.
- BCMab1 is a novel monoclonal antibody targeting this specific Integrin α3β1.
Observation:
- BCMab1 was conjugated with the ricin A chain to create BCMab1-Ra, an antibody-based drug.
- A patient with multiple bladder tumors received intravesical BCMab1-Ra treatment.
- Treatment involved administration directly into the bladder.
Findings:
- No tumor was observed via cystoscopy after 30 weeks of treatment.
- No local or systemic side effects were reported during the treatment period.
- Human anti-mouse antibody (HAMA) remained undetectable in circulation.
- Follow-up reviews over 3 years showed no tumor recurrence.
Implications:
- BCMab1-Ra demonstrates potential as an effective and safe intravesical therapy for bladder cancer.
- Targeting aberrantly glycosylated Integrin α3β1 offers a novel therapeutic strategy.
- Further clinical trials are warranted to validate these promising preliminary findings.
